Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF

Recently two novel drugs, pirfenidone and nintedanib have been licenced for the treatment of idiopathic pulmonary fibrosis (IPF), marking a turning point in this previously untreatable, fatal disease.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European respiratory journal 2015-10, Vol.46 (4), p.1217-1221
Hauptverfasser:	Milger, Katrin, Kneidinger, Nikolaus, Neurohr, Claus, Reichenberger, Frank, Behr, Jürgen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anti-Inflammatory Agents - therapeutic use Body Mass Index Compassionate Use Trials Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Female Humans Idiopathic Pulmonary Fibrosis - drug therapy Indoles - therapeutic use Male Middle Aged Pyridones - adverse effects Pyridones - therapeutic use Respiratory Function Tests Retrospective Studies Vital Capacity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recently two novel drugs, pirfenidone and nintedanib have been licenced for the treatment of idiopathic pulmonary fibrosis (IPF), marking a turning point in this previously untreatable, fatal disease.
ISSN:	0903-1936 1399-3003
DOI:	10.1183/13993003.00584-2015